arrow_back Back to IPOs
info

Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.

AN

Accretion Nutraveda

Listed SME BSE SME · Pharmaceuticals

Price Band

₹122.0–129.0

Issue Size

₹24.77 Cr

Lot Size

1,000 shares

Min Investment

₹258,000

GMP

+₹68.0 (52.71%)

Issue Price

₹129.0

calendar_month Important Dates

play_arrow
IPO Open Date
Wed, 28 Jan 2026
stop
IPO Close Date
Fri, 30 Jan 2026
assignment
Allotment Date
Mon, 02 Feb 2026
currency_rupee
Refund Initiation
Tue, 03 Feb 2026
account_balance
Credit of Shares
Tue, 03 Feb 2026
rocket_launch
Listing Date
Wed, 04 Feb 2026
Listing Price
₹197.0 +52.71%

bar_chart Subscription Status

info

Subscription data unavailable

trending_up Grey Market Premium (GMP)

GMP

+₹68.0

GMP %

+52.71%

Est. Listing

₹197.0

schedule Updated: 14 Jul 2026 15:52

business About the Company

Accretion Nutraveda is a manufacturer of Ayurvedic and nutraceutical formulations, offering a wide range of dosage forms such as tablets, capsules, syrups, powders, oils, and topical products, including balms, creams, and gels. The company functions as a Contract Development and Manufacturing Organization (CDMO), catering to both Indian and overseas clients. Its international footprint spans markets like Sri Lanka, Singapore, and the United States. By blending traditional Ayurvedic knowledge with contemporary nutraceutical research, Accretion Nutraveda develops products targeting key wellness areas such as liver health, women’s care, bone and joint support, brain health, and respiratory well-being. Business Verticals: Domestic Sales and Merchant Exports (Loan License Model): Accounted for approximately 96.62% of total revenue in FY 2024–25. Direct Exports: Contributed around 38% of revenue, reflecting steady and ongoing growth. The company operates a manufacturing unit in Gujarat with a built-up area of nearly 10,763 square feet. The facility is fitted with advanced infrastructure, including 13 air handling units, dedicated processing zones, and robust quality assurance systems. It holds multiple certifications such as GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal, and is also licensed by FSSAI, underscoring its strong compliance and quality standards.

payments Company Financials (₹ Cr)

As of 2025-09-30

Period Ended 30 Sep 2025 31 Mar 2025 31 Mar 2024 31 Mar 2023
Assets 16.35 10.86 4.64 4.06
Total Income 14.07 16.06 5.20 3.07
Profit After Tax 2.33 2.61 0.82 0.28
EBITDA 3.29 3.65 1.21 0.59
NET Worth 8.26 5.35 1.08 0.26
Reserves and Surplus 2.95 4.86 0.72 -0.10
Total Borrowing 4.43 3.86 2.17 1.97

Key Ratios

EPS

₹4.91

NAV

₹14.72

ROE

81.22%

ROCE

36.98%

RoNW

48.85%

P/B Value

8.76

P/E Ratio

26.27

Market Cap

₹93.40 Cr

PAT Margin

16.33%

Debt/Equity

0.72

Promoters

Mayur Popatlal Sojitra, Ankurkumar Shantilal Patel, Paraskumar Vinubhai Parmar, Hardik Mukundbhai Prajapati, Harshad Nanubhai Rathod and Vivek Ashok Kumar Patel

Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Purchase of Machineries for Automation in existing Manufacturing unit 4.22 2 Purchase of Machineries for New Manufacturing Setup 8.03 3 Funding working capital requirements of the Company 5.50 4 General Corporate Purposes 3.69 5 Issue Expenses 3.33 Total 24.77

info Issue Details

Issue Type SME Book Built
Issue Size ₹24.77 Cr
Price Band ₹122.0 – ₹129.0
Issue Price ₹129.0
Lot Size 1,000 shares
Min Investment ₹258,000
Exchange BSE SME
Sector Pharmaceuticals
Open Date 28 Jan 2026
Close Date 30 Jan 2026
Allotment 02 Feb 2026
Listing Date 04 Feb 2026

pie_chart Investor Allocation

QIB (Institutional) 50%
NII / HNI 15%
Retail (RII) 35%

Registrar

domain Kfin Technologies Ltd.

Lead Managers / Book Running

account_balance Sobhagya Capital Options Pvt.Ltd.

timeline IPO Timeline

check

Open

28 Jan 2026

check

Close

30 Jan 2026

check

Allotment

02 Feb 2026

check

Listing

04 Feb 2026

1